Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05631873 · ClinicalTrials.gov registry record · NA
Colonoscopy Screening: Setting Epic Follow-up Times
A NA study of Colorectal Cancer and Concordance Between Colonoscopy Follow up Interval Noted in Patient Letters vs. Electronic Health Record Chart, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT05631873 is a NA study of Colorectal Cancer and Concordance Between Colonoscopy Follow up Interval Noted in Patient Letters vs. Electronic Health Record Chart that has completed, run by Massachusetts General Hospital. The registered enrollment target is 43 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05631873, a NA study of Colorectal Cancer and Concordance Between Colonoscopy Follow up Interval Noted in Patient Letters vs. Electronic Health Record Chart, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
Screening for colorectal cancer can reduce its incidence and mortality but is a complex, error-prone process. The value of screening with colonoscopy is in removing pre-cancerous polyps that increase one's risk for future cancer. Abnormal results are common, and failure to receive recommended follow-up undermines the benefits of screening, violates the trust that patients place in their providers, and increases medicolegal risk. This proposal seeks to ensure that the foundation of safety systems, the recommendations for the follow-up interval reflect current guideline recommendations and are accurately updated. Specifically, the investigators will implement and evaluate in a randomized trial a new colonoscopy result letter as part of usual care that automatically updates the recommended follow-up interval in the patient's health record compared to the current result letter format.
Conditions Studied
Interventions
- OTHER Assistance with implementing Epic Smartlist
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2022-11-18 |
| Est. Completion | 2024-03-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05631873
The ClinicalTrials.gov registry entry for NCT05631873 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Assistance with implementing Epic Smartlist is the first listed.
NCT05631873 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05631873 about?
NCT05631873 is a clinical study titled "Colonoscopy Screening: Setting Epic Follow-up Times". Screening for colorectal cancer can reduce its incidence and mortality but is a complex, error-prone process. The value of screening with colonoscopy is in removing pre-cancerous polyps that increase one's risk for future cancer. Abnormal results are common, and failure to receive recommended follow...
What is the current status of trial NCT05631873?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2022-11-18. Estimated completion is 2024-03-11.
What conditions does trial NCT05631873 study?
This clinical trial studies the following conditions: Colorectal Cancer, Concordance Between Colonoscopy Follow up Interval Noted in Patient Letters vs. Electronic Health Record Chart.
What interventions are being tested in trial NCT05631873?
The interventions under investigation include: Assistance with implementing Epic Smartlist (OTHER).
Who is sponsoring clinical trial NCT05631873?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05631873 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery
RECRUITING · NA
-
Ultrasound and Photoacoustic Imaging for Enhanced Differential Diagnosis of Rectal Cancer
RECRUITING · NA
-
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
RECRUITING · NA
Explore more on PlainTrial
Colorectal Cancer
All registered trials for this condition
Concordance Between Colonoscopy Follow up Interval Noted in Patient Letters vs. Electronic Health Record Chart
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.